Gilead Sciences Stock Today
| GILD Stock | USD 111.53 0.50 0.45% |
PerformanceSolid
| Odds Of DistressLow
|
Gilead Sciences is trading at 111.53 as of the 26th of February 2025, a 0.45 percent increase since the beginning of the trading day. The stock's lowest day price was 110.1. Gilead Sciences has less than a 9 % chance of experiencing financial distress in the next few years and had a solid performance during the last 90 days. Note, on December 30, 2024, Representative Marjorie Taylor Greene of US Congress acquired under $15k worth of Gilead Sciences's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of January 1992 | Category Healthcare | Classification Health Care |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company was incorporated in 1987 and is headquartered in Foster City, California. The company has 1.25 B outstanding shares of which 22.93 M shares are currently shorted by private and institutional investors with about 3.43 trading days to cover. More on Gilead Sciences
Moving together with Gilead Stock
Moving against Gilead Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Gilead Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman of the Board, CEO | Daniel ODay | ||||
| Thematic Ideas | (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Nasdaq 100, SP 500 Index, NASDAQ 100 Equal, SP 100 Index, SP 100, Nasdaq 100 Total, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ 100 Pre, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, BETTERINVESTING 100 INDEX, Macroaxis Index, Corona Opportunity, Health Care, Biotechnology, Drug Manufacturers—General, Healthcare (View all Sectors) | ||||
| Excise Tax Activities | Animal Testing | ||||
| Average Analyst Recommendation | |||||
Debt LevelsGilead Sciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Gilead Sciences' financial leverage. It provides some insight into what part of Gilead Sciences' total assets is financed by creditors.
| |||||
Gilead Sciences (GILD) is traded on NASDAQ Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA, United States, 94404 and employs 18 people. Gilead Sciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 139 B. Gilead Sciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.25 B outstanding shares of which 22.93 M shares are currently shorted by private and institutional investors with about 3.43 trading days to cover.
Gilead Sciences currently holds about 6.14 B in cash with 10.83 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9.
Check Gilead Sciences Probability Of Bankruptcy
Ownership AllocationGilead Sciences has a total of 1.25 Billion outstanding shares. The majority of Gilead Sciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Gilead Sciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Gilead Sciences. Please pay attention to any change in the institutional holdings of Gilead Sciences as this could imply that something significant has changed or is about to change at the company. On December 30, 2024, Representative Marjorie Taylor Greene of US Congress acquired under $15k worth of Gilead Sciences's common stock.
Check Gilead Ownership Details
Gilead Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2024-12-31 | 17.7 M | |
| Bank Of New York Mellon Corp | 2024-12-31 | 16.8 M | |
| Northern Trust Corp | 2024-12-31 | 14.9 M | |
| Jpmorgan Chase & Co | 2024-09-30 | 13.3 M | |
| Ubs Asset Mgmt Americas Inc | 2024-12-31 | 12.2 M | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 11.6 M | |
| Amvescap Plc. | 2024-12-31 | 11.3 M | |
| Legal & General Group Plc | 2024-12-31 | 9.9 M | |
| Amundi | 2024-12-31 | 9 M | |
| Blackrock Inc | 2024-12-31 | 120.4 M | |
| Vanguard Group Inc | 2024-12-31 | 115.5 M |
Gilead Sciences Historical Income Statement
Gilead Stock Against Markets
Gilead Sciences Corporate Management
| SeeChun MD | VP Oncology | Profile | |
| Monica Tijerina | Clinical Manufacturing | Profile | |
| Johanna Mercier | Chief Commercial Officer | Profile | |
| Bilal Piperdi | Vice Oncology | Profile | |
| Jackson Egen | Vice Oncology | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.258 | Dividend Share 3.08 | Earnings Share 0.38 | Revenue Per Share | Quarterly Revenue Growth 0.064 |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.